The new UK clinical trials regime will accelerate the approval process for new medicines and enable patients to access treatments sooner while giving pharmaceutical companies a faster and more predictable pathway to bring therapeutics to market.
Following parliamentary approval in April 2025, significant changes to the Medicines for Human Use (Clinical Trials) Regulations 2004 (the Regulations) are due to come into force on 28 April 2026. In developing the framework, the Medicines and Healthcare products Regulatory Agency (MHRA) has emphasised its commitment to designing “a flexible and risk-proportionate regulation of clinical trials, which accelerates patient access to potentially life-saving medicines without compromising safety.”
Once implemented, all clinical trials in the UK will have to comply with the updated Regulations. The new regime will overhaul the current regulations dating back to 2004 and aims to modernise the way in which trials involving medicinal products are conducted. In general, the reforms are aimed at simplifying/expediting approval processes for clinical trials and will align the UK more closely with the EU position.
Important updates include:
- A fast-track notification system allowing low risk trials to begin more quickly – this fast-track route is expected to impact around 20% of studies.
- A new 14-day assessment route for Phase 1 healthy volunteer trials.
- Expanded use of early safety data from international studies that meet UK standards, alongside a fast-track notification system allowing low risk trials to begin more quickly.
- A binding 30‑day timeline for initial application reviews, improving predictability for sponsors.
- Enhanced MHRA capacity to assess computer model simulations that can predict the behaviour of new medicines before they are tested in humans.
The updated Good Clinical Practice guidelines will take effect alongside the Regulations and, in keeping with an increased emphasis on transparency, compliance with the internationally recognised principles set out in the Declaration of Helsinki will be required for all clinical trials. The Declaration sets ethical standards for medical research involving human participants, including requirements on informed consent, risk‑benefit assessment and the use of placebos.
Both the MHRA and the Health Research Authority have published guidance that will help the clinical trial community to prepare for the implementation of the updated Regulations. The reforms are expected to deliver wide-ranging benefits for researchers, health professionals and patients by establishing a modernised, faster and more flexible clinical trials framework in the UK.
